{
  "meta": {
    "title": "22_Drugs_For_Pud",
    "url": "https://brainandscalpel.vercel.app/22-drugs-for-pud-2cdc18fe.html",
    "scrapedAt": "2025-11-30T06:59:46.222Z"
  },
  "questions": [
    {
      "id": 88813,
      "choices": [
        {
          "id": 273837,
          "text": "Vitamin B12 deficiency"
        },
        {
          "id": 273838,
          "text": "Hyperuricaemia"
        },
        {
          "id": 273839,
          "text": "Hyperglycemia"
        },
        {
          "id": 273840,
          "text": "Osteomalacia"
        }
      ],
      "text": "Long term of aluminum hydroxide can cause",
      "unique_key": "Q2900809",
      "question_audio": null,
      "question_video": null,
      "map_id": 34347138,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Osteomalacia. Long-term use of aluminum hydroxide, an antacid, can lead to osteomalacia (softening of bones) due to phosphate depletion. Aluminum binds to dietary phosphate in the gut, reducing its absorption. Since phosphate is essential for bone mineralization, chronic deficiency leads to weak, brittle bones, fractures, and musculoskeletal pain. This condition is especially concerning in patients with chronic kidney disease (CKD), where phosphate balance is already disrupted. Additionally, aluminum can accumulate in bones, further impairing bone metabolism. Explanation of Incorrect Options: (A) Vitamin B12 deficiency: This is incorrect because aluminum hydroxide does not interfere with Vitamin B12 absorption. While some antacids (like proton pump inhibitors) may reduce stomach acidity and affect B12 absorption over time, aluminum hydroxide primarily binds phosphate rather than impacting intrinsic factor or gastric acid secretion. (B) Hyperuricemia: This is incorrect because aluminum hydroxide does not increase uric acid levels. Hyperuricemia is commonly associated with conditions like gout, kidney disease, and diuretics, but aluminum hydroxide does not influence uric acid metabolism. (C) Hyperglycemia: This is incorrect because aluminum hydroxide does not affect blood glucose levels or insulin secretion. Hyperglycemia is typically linked to diabetes, corticosteroid use, or metabolic disorders, not antacid therapy.",
      "correct_choice_id": 273840,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/74909001700129018/74909001700129018.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/74909001700129018/74909001700129018.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 88814,
      "choices": [
        {
          "id": 273841,
          "text": "Spontaneous bacterial peritonitis in patients with ascites"
        },
        {
          "id": 273842,
          "text": "Increased risk of bone fracture"
        },
        {
          "id": 273843,
          "text": "Vitamin B 12 Deficiency"
        },
        {
          "id": 273844,
          "text": "Hypergastrinemia"
        }
      ],
      "text": "Chronic treatment with omeprazole causes following ADRs except",
      "unique_key": "Q1599127",
      "question_audio": null,
      "question_video": null,
      "map_id": 34827994,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Hypergastrinemia. While omeprazole, a proton pump inhibitor (PPI), can cause elevated gastrin levels (hypergastrinemia) due to chronic suppression of gastric acid, this is not classified as an adverse drug reaction (ADR) in the clinical sense. Instead, it is a physiological compensatory response to prolonged acid suppression. The reduced acidity in the stomach leads to increased gastrin secretion from G-cells to stimulate acid production, but since PPIs block proton pumps, this does not effectively increase acid output. Though long-term hypergastrinemia can lead to ECL cell hyperplasia or gastric polyps, it is not an immediate or common ADR of omeprazole therapy. Explanation of Incorrect Options: (A) Spontaneous bacterial peritonitis (SBP) in patients with ascites: This is correct. PPIs like omeprazole increase the risk of infections, including SBP in patients with cirrhosis and ascites. The mechanism involves gut microbiota alterations and bacterial overgrowth, leading to higher bacterial translocation into the peritoneal cavity, which can trigger SBP. (B) Increased risk of bone fracture: This is correct. Chronic omeprazole use has been associated with an increased risk of osteoporosis-related fractures, particularly of the hip, spine, and wrist. This occurs due to impaired calcium absorption, as stomach acid is necessary for calcium solubilization and uptake. Prolonged acid suppression reduces calcium bioavailability, leading to decreased bone mineral density. (C) Vitamin B?? Deficiency: This is correct. Omeprazole reduces gastric acid secretion, which is essential for the cleavage of Vitamin B?? from dietary proteins. Over time, this can lead to B?? deficiency, resulting in megaloblastic anemia, neurological deficits, and peripheral neuropathy in chronic users, especially the elderly.",
      "correct_choice_id": 273844,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/51242981700129051/51242981700129051.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/51242981700129051/51242981700129051.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 88815,
      "choices": [
        {
          "id": 273845,
          "text": "80 mg"
        },
        {
          "id": 273846,
          "text": "160 mg"
        },
        {
          "id": 273847,
          "text": "120 mg"
        },
        {
          "id": 273848,
          "text": "40 mg"
        }
      ],
      "text": "FDA-approved dose of intravenous pantoprazole for gastroesophageal reflux disease daily is",
      "unique_key": "Q1731382",
      "question_audio": null,
      "question_video": null,
      "map_id": 34888279,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) 40 mg. The FDA-approved dose of intravenous (IV) pantoprazole for gastroesophageal reflux disease (GERD) is 40 mg once daily. Pantoprazole is a proton pump inhibitor (PPI) that inhibits gastric acid secretion by irreversibly blocking the H+/K+-ATPase enzyme in the parietal cells of the stomach. The IV formulation is used when oral administration is not possible, such as in hospitalized patients with severe GERD, erosive esophagitis, or Zollinger-Ellison syndrome. Studies have shown that 40 mg IV once daily is effective in acid suppression and symptom relief, making it the standard approved dose for GERD. Incorrect Options: (A) 80 mg: This is incorrect because 80 mg IV pantoprazole is typically used for upper gastrointestinal bleeding rather than GERD. In conditions like peptic ulcer bleeding, an initial IV bolus of 80 mg followed by a continuous infusion of 8 mg/hour for 72 hours is recommended. However, this is not the standard dose for GERD. (B) 160 mg: This is incorrect because such high doses are not approved for GERD. Doses of 120–160 mg/day may be used off-label for hypersecretory conditions like Zollinger-Ellison syndrome, but they are not FDA-approved for GERD management. (C) 120 mg: This is incorrect because similar to 160 mg, this dose is used for pathological hypersecretory states rather than GERD. High-dose IV pantoprazole may be required in gastrinoma cases, but not for routine GERD treatment.",
      "correct_choice_id": 273848,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/74816511700129085/74816511700129085.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/74816511700129085/74816511700129085.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 88816,
      "choices": [
        {
          "id": 273849,
          "text": "H+Na+ ATPase pump"
        },
        {
          "id": 273850,
          "text": "Na+K+ ATPase pump"
        },
        {
          "id": 273851,
          "text": "H+K+ ATPase pump"
        },
        {
          "id": 273852,
          "text": "All of the above"
        }
      ],
      "text": "Which of the following is inhibited by Lansoprazole",
      "unique_key": "Q9385566",
      "question_audio": null,
      "question_video": null,
      "map_id": 34791133,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) H+/K+ ATPase pump. Lansoprazole is a proton pump inhibitor (PPI) that selectively inhibits the H+/K+ ATPase enzyme located in the parietal cells of the stomach. This pump is responsible for the final step of gastric acid secretion, where hydrogen ions are actively transported into the gastric lumen in exchange for potassium ions. By irreversibly binding to this enzyme, Lansoprazole effectively suppresses gastric acid secretion, making it useful for conditions such as gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome. The inhibition lasts until new proton pumps are synthesized, leading to prolonged acid suppression despite the drug’s short half-life. Incorrect Options: (A) H+/Na+ ATPase pump: This is incorrect because there is no known H+/Na+ ATPase pump involved in gastric acid secretion. The primary transporter responsible for acid secretion in the stomach is the H+/K+ ATPase pump, which is specifically targeted by Lansoprazole. (B) Na+/K+ ATPase pump: This is incorrect because the Na+/K+ ATPase pump is different from the proton pump and is found in almost all cells, playing a crucial role in maintaining sodium and potassium balance across cell membranes. It helps in nerve signal transmission and muscle contraction but has no direct role in acid secretion. Lansoprazole does not inhibit this pump. (D) All of the above: This is incorrect because Lansoprazole only inhibits the H+/K+ ATPase pump in the gastric parietal cells, not the Na+/K+ ATPase or any hypothetical H+/Na+ ATPase pump.",
      "correct_choice_id": 273851,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/36552561700129104/36552561700129104.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/36552561700129104/36552561700129104.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 88817,
      "choices": [
        {
          "id": 273853,
          "text": "Ranitidine and cimetidine have wide pharmacokinetic variability"
        },
        {
          "id": 273854,
          "text": "Ranitidine is about 5 times more potent than cimetidine"
        },
        {
          "id": 273855,
          "text": "Ranitidine has no antiandrogenic action"
        },
        {
          "id": 273856,
          "text": "Ranitidine has lesser drug interactions compared to cimetidine"
        }
      ],
      "text": "Following are differences between Ranitidine and Cimetidine except",
      "unique_key": "Q9411898",
      "question_audio": null,
      "question_video": null,
      "map_id": 34784943,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Ranitidine and cimetidine have wide pharmacokinetic variability. This statement is incorrect because Ranitidine has more predictable pharmacokinetics compared to Cimetidine. Cimetidine exhibits significant interindividual variability due to its extensive metabolism and inhibition of cytochrome P450 (CYP) enzymes, leading to variable drug levels and interactions. In contrast, Ranitidine has a more consistent absorption, metabolism, and elimination, making its pharmacokinetics more predictable. Thus, while Cimetidine has wide pharmacokinetic variability, Ranitidine does not, making option (A) incorrect. Incorrect Options: (B) Ranitidine is about 5 times more potent than Cimetidine: This is correct. Ranitidine is a second-generation H? receptor antagonist and is approximately 5 times more potent than Cimetidine in inhibiting gastric acid secretion. This means a lower dose of Ranitidine achieves the same acid-suppressing effect as a higher dose of Cimetidine. (C) Ranitidine has no antiandrogenic action: This is correct. Cimetidine has antiandrogenic effects because it blocks androgen receptors and inhibits testosterone metabolism, potentially leading to gynecomastia, decreased libido, and impotence in long-term users. Ranitidine, however, does not exhibit these antiandrogenic effects, making it safer in this regard. (D) Ranitidine has lesser drug interactions compared to Cimetidine: This is correct. Cimetidine is a strong inhibitor of cytochrome P450 enzymes (CYP1A2, CYP2C9, CYP2D6, and CYP3A4), leading to numerous drug interactions by slowing the metabolism of drugs like warfarin, phenytoin, theophylline, and benzodiazepines. Ranitidine has much weaker CYP inhibition, resulting in fewer drug interactions.",
      "correct_choice_id": 273853,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/72315181700129122/72315181700129122.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/72315181700129122/72315181700129122.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 88818,
      "choices": [
        {
          "id": 273857,
          "text": "Nizatidine"
        },
        {
          "id": 273858,
          "text": "Cimetidine"
        },
        {
          "id": 273859,
          "text": "Ranitidine"
        },
        {
          "id": 273860,
          "text": "All of the above"
        }
      ],
      "text": "Which of the following H2 blocker has no interaction with hepatic CYPs",
      "unique_key": "Q9463741",
      "question_audio": null,
      "question_video": null,
      "map_id": 34712334,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Nizatidine. Among the H2 receptor blockers, Nizatidine has no significant interaction with hepatic cytochrome P450 (CYP) enzymes. It undergoes minimal hepatic metabolism and is primarily excreted unchanged by the kidneys, making it the safest option in terms of drug interactions. Due to this property, Nizatidine does not affect the metabolism of other drugs that rely on CYP enzymes, unlike other H2 blockers such as Cimetidine and Ranitidine. This makes it particularly useful in patients taking multiple medications where CYP-mediated drug interactions are a concern. Incorrect Options: (B) Cimetidine: This is incorrect because Cimetidine is a strong inhibitor of multiple CYP enzymes (CYP1A2, CYP2C9, CYP2D6, and CYP3A4). This leads to significant drug interactions, prolonging the half-life of drugs like warfarin, phenytoin, theophylline, and benzodiazepines, potentially causing toxicity. Cimetidine's CYP inhibition is one of its major limitations in clinical use. (C) Ranitidine: This is incorrect because Ranitidine weakly inhibits CYP enzymes, though to a much lesser extent than Cimetidine. While it has fewer drug interactions compared to Cimetidine, it still has some potential for CYP-mediated interactions. (D) All of the above: This is incorrect because only Nizatidine completely lacks interaction with hepatic CYP enzymes, whereas both Cimetidine and Ranitidine do interact with CYPs to varying degrees.",
      "correct_choice_id": 273857,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/71243371700129137/71243371700129137.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/71243371700129137/71243371700129137.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 88819,
      "choices": [
        {
          "id": 273861,
          "text": "Cisapride"
        },
        {
          "id": 273862,
          "text": "Domperidone"
        },
        {
          "id": 273863,
          "text": "Itopride"
        },
        {
          "id": 273864,
          "text": "Metoclopropamide"
        }
      ],
      "text": "Prokinetic drug which is mainly metabolized by Flavin monooxygenases is",
      "unique_key": "Q7248538",
      "question_audio": null,
      "question_video": null,
      "map_id": 34405704,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Itopride. Itopride is a prokinetic drug primarily metabolized by flavin-containing monooxygenases (FMO enzymes), rather than cytochrome P450 (CYP) enzymes. FMOs are involved in the oxidation of nitrogen- and sulfur-containing compounds, and their activity is less prone to drug interactions compared to CYP enzymes. Because Itopride does not significantly involve CYP enzymes, it has a lower risk of drug interactions, making it a safer choice for patients on multiple medications. Additionally, Itopride exerts both dopamine D? receptor antagonism and acetylcholinesterase inhibition, enhancing gastric motility with a reduced risk of cardiac adverse effects seen with other prokinetics. Explanation of Incorrect Options: (A) Cisapride: This is incorrect because Cisapride is primarily metabolized by CYP3A4, a hepatic enzyme. CYP3A4 metabolism makes it highly susceptible to drug interactions, leading to QT prolongation and fatal cardiac arrhythmias (torsades de pointes), which led to its withdrawal in many countries. (B) Domperidone: This is incorrect because Domperidone is primarily metabolized by CYP3A4. Like Cisapride, its metabolism by CYP3A4 increases its potential for drug interactions and QT prolongation. However, it does not significantly cross the blood-brain barrier, reducing central nervous system (CNS) side effects. (D) Metoclopramide: This is incorrect because Metoclopramide undergoes hepatic metabolism primarily by CYP2D6. It also crosses the blood-brain barrier, leading to CNS side effects such as extrapyramidal symptoms and tardive dyskinesia, particularly with long-term use.",
      "correct_choice_id": 273863,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/25828481700129151/25828481700129151.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/25828481700129151/25828481700129151.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 88820,
      "choices": [
        {
          "id": 273865,
          "text": "Metacloprapimde prokinetic action is not attenuated by atropine"
        },
        {
          "id": 273866,
          "text": "Domperidone prokinetic action is attenuated by atropine"
        },
        {
          "id": 273867,
          "text": "Domperidone prokinetic action is not attenuated by atropine"
        },
        {
          "id": 273868,
          "text": "None of the above"
        }
      ],
      "text": "True statement about Prokinetic action of domperidone and metacloprapimde is",
      "unique_key": "Q9180117",
      "question_audio": null,
      "question_video": null,
      "map_id": 34106027,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Domperidone prokinetic action is not attenuated by atropine. Domperidone is a dopamine D2 receptor antagonist that enhances gastrointestinal motility by blocking dopaminergic inhibition of acetylcholine release in the myenteric plexus. Unlike Metoclopramide, Domperidone does not have significant cholinergic activity, meaning its prokinetic action is not affected by atropine, which is a muscarinic antagonist. Since atropine primarily blocks cholinergic (muscarinic) receptors, it does not counteract the dopamine-mediated prokinetic action of Domperidone. Incorrect Options: (A) Metoclopramide prokinetic action is not attenuated by atropine: This is incorrect because Metoclopramide exerts both dopamine D2 receptor antagonism and direct cholinergic effects by enhancing acetylcholine release. Since atropine blocks muscarinic receptors, it can attenuate the cholinergic component of Metoclopramide’s prokinetic action, though some effect may still remain due to D2 antagonism. (B) Domperidone prokinetic action is attenuated by atropine: This is incorrect because Domperidone’s prokinetic action is purely due to D2 receptor blockade, without significant cholinergic involvement. Atropine, which blocks muscarinic receptors, has no effect on Domperidone’s mechanism of action. (D) None of the above: This is incorrect because statement (C) is correct, meaning this option does not apply.",
      "correct_choice_id": 273867,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/67525941700129168/67525941700129168.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/67525941700129168/67525941700129168.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 88821,
      "choices": [
        {
          "id": 273869,
          "text": "Central D2 antagonism"
        },
        {
          "id": 273870,
          "text": "Peripheral D2 antagonism"
        },
        {
          "id": 273871,
          "text": "5-HT4 agonism"
        },
        {
          "id": 273872,
          "text": "Both B and C"
        }
      ],
      "text": "The prokinetic activity of metoclopramide is mainly because of",
      "unique_key": "Q9784403",
      "question_audio": null,
      "question_video": null,
      "map_id": 34964861,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Both B and C. The prokinetic activity of Metoclopramide is primarily due to its peripheral D2 receptor antagonism and 5-HT4 receptor agonism. Peripheral D2 antagonism: In the gastrointestinal (GI) tract, dopamine normally inhibits acetylcholine (ACh) release from the myenteric plexus, leading to reduced motility. By blocking peripheral D2 receptors, Metoclopramide removes this inhibitory effect, leading to increased ACh release, which enhances gastric emptying and intestinal motility. 5-HT4 receptor agonism: Metoclopramide also acts as a serotonin 5-HT4 receptor agonist, which further stimulates ACh release in the enteric nervous system, promoting peristalsis and gastric emptying. This additional mechanism enhances its prokinetic activity beyond D2 antagonism alone. Incorrect Options: (A) Central D2 antagonism: This is incorrect because central D2 antagonism is responsible for Metoclopramide’s antiemetic effect, not its prokinetic action. By blocking D2 receptors in the chemoreceptor trigger zone (CTZ), it prevents nausea and vomiting, but this mechanism does not directly contribute to its prokinetic effects. (B) Peripheral D2 antagonism: This is partially correct, but not the only mechanism responsible for Metoclopramide’s prokinetic activity. While peripheral D2 antagonism plays a major role, 5-HT4 agonism also significantly contributes to increased gut motility. (C) 5-HT4 agonism: This is partially correct, but again, not the sole mechanism. 5-HT4 agonism promotes ACh release, enhancing GI motility, but without D2 antagonism, its effect would be incomplete.",
      "correct_choice_id": 273872,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/53215651700129181/53215651700129181.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/53215651700129181/53215651700129181.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 88822,
      "choices": [
        {
          "id": 273873,
          "text": "They have rapid as well as sustained acid neutralizing action"
        },
        {
          "id": 273874,
          "text": "They are less likely to affect gastric emptying"
        },
        {
          "id": 273875,
          "text": "They are less likely to alter bowel movement"
        },
        {
          "id": 273876,
          "text": "All of the above"
        }
      ],
      "text": "Antacid combinations of magnesium and aluminum salts are superior to single component preparations because",
      "unique_key": "Q3091499",
      "question_audio": null,
      "question_video": null,
      "map_id": 34280261,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) All of the above. Combination antacid formulations containing both magnesium and aluminum salts offer several advantages over single-component preparations. Magnesium hydroxide acts rapidly to neutralize gastric acid, while aluminum hydroxide provides a more prolonged effect. Additionally, the opposing effects of these two components on gastrointestinal motility balance each other, minimizing side effects such as diarrhea or constipation. Explanation of Individual Options: (A) They have rapid as well as sustained acid-neutralizing action: Magnesium hydroxide acts quickly to neutralize stomach acid, providing immediate relief from hyperacidity. Aluminum hydroxide reacts more slowly but has a prolonged effect, helping to maintain a sustained reduction in gastric acidity. (B) They are less likely to affect gastric emptying: Aluminum-containing antacids tend to delay gastric emptying, while magnesium-containing antacids can promote gastric motility. The combination results in a more balanced effect, reducing the risk of altered gastric emptying. (C) They are less likely to alter bowel movement: Magnesium hydroxide has a laxative effect and can cause diarrhea when used alone. Aluminum hydroxide has an astringent effect and can lead to constipation when used alone. A combination of both helps balance these effects, reducing the risk of bowel disturbances.",
      "correct_choice_id": 273876,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/74801281700129461/74801281700129461.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/74801281700129461/74801281700129461.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 88823,
      "choices": [
        {
          "id": 273877,
          "text": "Carbenoxolone sodium"
        },
        {
          "id": 273878,
          "text": "Sucralfate"
        },
        {
          "id": 273879,
          "text": "Misoprostol"
        },
        {
          "id": 273880,
          "text": "Colloidal bismuth subcitrate"
        }
      ],
      "text": "Choose the antiulcer drug that inhibits gastric acid secretion, stimulates gastric mucus anti bicarbortate secretion and has cytoprotective action on gastric mucosa",
      "unique_key": "Q9593032",
      "question_audio": null,
      "question_video": null,
      "map_id": 34881998,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Misoprostol. Misoprostol is a prostaglandin E1 (PGE1) analog that acts as an antiulcer agent by multiple mechanisms. It inhibits gastric acid secretion by binding to prostaglandin receptors on parietal cells, reducing cyclic AMP and subsequently decreasing acid production. Additionally, it stimulates the secretion of gastric mucus and bicarbonate, enhancing the gastric mucosal barrier and providing cytoprotective effects. Because of these actions, misoprostol is particularly useful in preventing NSAID-induced gastric ulcers. Explanation of Incorrect Options: (A) Carbenoxolone sodium: Carbenoxolone primarily enhances mucus secretion and promotes ulcer healing but does not significantly inhibit gastric acid secretion. It is derived from glycyrrhizin (found in licorice) and helps strengthen the mucosal barrier. (B) Sucralfate: Sucralfate acts by forming a protective gel-like barrier over the ulcer, shielding it from acid and pepsin. However, it does not directly inhibit acid secretion or stimulate bicarbonate secretion. (D) Colloidal bismuth subcitrate (CBS): CBS exerts a cytoprotective effect by coating ulcers and promoting mucus and bicarbonate secretion. However, it does not significantly inhibit gastric acid secretion like misoprostol.",
      "correct_choice_id": 273879,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/43501321700129477/43501321700129477.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/43501321700129477/43501321700129477.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 88824,
      "choices": [
        {
          "id": 273881,
          "text": "Esomeprazole"
        },
        {
          "id": 273882,
          "text": "Loxatidine"
        },
        {
          "id": 273883,
          "text": "Misoprostol"
        },
        {
          "id": 273884,
          "text": "Pirenzepine"
        }
      ],
      "text": "Drug of choice for the treatment of peptic ulcer caused due to chronic use of NSAIDs is",
      "unique_key": "Q2616905",
      "question_audio": null,
      "question_video": null,
      "map_id": 34619251,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Esomeprazole. Esomeprazole is a proton pump inhibitor (PPI) that effectively reduces gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase pump in parietal cells. This profound suppression of acid production helps in the healing of NSAID-induced peptic ulcers and prevents their recurrence. PPIs, including esomeprazole, are the first-line therapy for peptic ulcers caused by chronic NSAID use because they provide superior acid suppression, faster ulcer healing, and prolonged symptom relief compared to other agents. Explanation of Incorrect Options: (B) Loxatidine: Loxatidine is an H+ receptor antagonist (H2RA) that reduces acid secretion but is less effective than PPIs in healing NSAID-induced ulcers. H2RAs are not the preferred treatment for NSAID-related ulcers due to their shorter duration of acid suppression and lower efficacy. (C) Misoprostol: Misoprostol, a prostaglandin E1 analog, reduces acid secretion and enhances mucosal protection by increasing bicarbonate and mucus secretion. While effective in preventing NSAID-induced ulcers, it is less effective than PPIs in healing existing ulcers and is associated with gastrointestinal side effects such as diarrhea and abdominal cramps. (D) Pirenzepine: Pirenzepine is an M1-selective antimuscarinic agent that inhibits gastric acid secretion by blocking vagal stimulation of parietal cells. However, it is not commonly used for NSAID-induced ulcers due to lower efficacy and significant anticholinergic side effects.",
      "correct_choice_id": 273881,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/67804751700129490/67804751700129490.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/67804751700129490/67804751700129490.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 88825,
      "choices": [
        {
          "id": 273885,
          "text": "Colloidal bismuth directly inhibits H. pylori but has poor patient acceptability"
        },
        {
          "id": 273886,
          "text": "Resistance to any single antimicrobial drug develops rapidly"
        },
        {
          "id": 273887,
          "text": "Concurrent suppression of gastric acid enhances the efficacy of the regimen"
        },
        {
          "id": 273888,
          "text": "It is indicated in all patients of peptic ulcer"
        }
      ],
      "text": "The following is true of anti-H. pylori therapy EXCEPT",
      "unique_key": "Q3550894",
      "question_audio": null,
      "question_video": null,
      "map_id": 34483586,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) It is indicated in all patients of peptic ulcer. Anti-H. pylori therapy is not indicated for all peptic ulcer patients because some ulcers are not caused by H. pylori infection but rather by NSAID use, stress, or other factors. While H. pylori eradication therapy is recommended for patients with confirmed H. pylori-associated ulcers, it is not necessary for patients with non-H. pylori, non-NSAID ulcers. In such cases, treatment with proton pump inhibitors (PPIs) alone is sufficient. Explanation of Incorrect Options: (A) Colloidal bismuth directly inhibits H. pylori but has poor patient acceptability: True. Colloidal bismuth compounds (e.g., bismuth subsalicylate) inhibit H. pylori growth, prevent adhesion to gastric mucosa, and have mild antibacterial effects. However, poor patient acceptability arises due to side effects such as black stools, darkened tongue, and frequent dosing requirements. (B) Resistance to any single antimicrobial drug develops rapidly: True. H. pylori exhibits high resistance to single antibiotics (especially clarithromycin and metronidazole), leading to treatment failure when monotherapy is used. To prevent resistance, triple therapy (PPI + two antibiotics) or quadruple therapy (PPI + bismuth + two antibiotics) is used. (C) Concurrent suppression of gastric acid enhances the efficacy of the regimen: True. Reducing gastric acid secretion (using PPIs or H? blockers) enhances antibiotic efficacy by improving drug stability and penetration in the gastric mucosa. PPIs also promote ulcer healing and increase H. pylori susceptibility to antibiotics.",
      "correct_choice_id": 273888,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/68964991700129521/68964991700129521.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/68964991700129521/68964991700129521.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 88826,
      "choices": [
        {
          "id": 273889,
          "text": "It causes prolonged naturalization of gastric acid"
        },
        {
          "id": 273890,
          "text": "It relieves peptic ulcer pain promptly"
        },
        {
          "id": 273891,
          "text": "It has anti H. pylori activity"
        },
        {
          "id": 273892,
          "text": "All of the above are correct"
        }
      ],
      "text": "Choose the CORRECT statement about colloidal bismuth subcitrate",
      "unique_key": "Q6306881",
      "question_audio": null,
      "question_video": null,
      "map_id": 34130194,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) It has anti-H. pylori activity. Colloidal bismuth subcitrate (CBS) has direct anti-H. pylori activity by inhibiting bacterial enzymes, preventing adhesion to the gastric mucosa, and disrupting bacterial cell membranes. Additionally, CBS forms a protective barrier over ulcerated areas, promoting healing and mucosal defense. Because of its anti-H. pylori effects, CBS is often included in quadruple therapy for H. pylori eradication along with a proton pump inhibitor (PPI) and two antibiotics. Explanation of Incorrect Options: (A) It causes prolonged neutralization of gastric acid – Incorrect. CBS does not neutralize gastric acid significantly like antacids (e.g., magnesium hydroxide, aluminum hydroxide). Instead, it binds to ulcer sites, creating a protective coating that shields the mucosa from acid and pepsin. (B) It relieves peptic ulcer pain promptly – Incorrect. While CBS helps ulcer healing, it does not provide immediate pain relief like antacids or proton pump inhibitors (PPIs). Pain relief occurs gradually as the ulcer heals over time. (D) All of the above are correct – Incorrect. Since statements (A) and (B) are incorrect, option (D) is also incorrect.",
      "correct_choice_id": 273891,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/26740371700132776/26740371700132776.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/26740371700132776/26740371700132776.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 88827,
      "choices": [
        {
          "id": 273893,
          "text": "Sucralfate"
        },
        {
          "id": 273894,
          "text": "Megaldrate"
        },
        {
          "id": 273895,
          "text": "Misoprostol"
        },
        {
          "id": 273896,
          "text": "Omeprazole"
        }
      ],
      "text": "The following anti-ulcer drug DOES NOT act by reducing the secretion of or neutralizing gastric acid",
      "unique_key": "Q7780202",
      "question_audio": null,
      "question_video": null,
      "map_id": 34748209,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Sucralfate. Sucralfate does not act by reducing gastric acid secretion or neutralizing acid. Instead, it works by forming a protective barrier over ulcerated areas. In an acidic environment (pH Explanation of Incorrect Options: (B) Megaldrate – Incorrect. Megaldrate is an antacid that neutralizes gastric acid, raising pH and reducing pepsin activity. It provides symptomatic relief from acid-related discomfort and helps in ulcer healing by reducing acidity. (C) Misoprostol – Incorrect. Misoprostol is a prostaglandin E1 analog that reduces gastric acid secretion by inhibiting adenylate cyclase in parietal cells. It also enhances mucus and bicarbonate secretion, contributing to mucosal protection. (D) Omeprazole – Incorrect. Omeprazole is a proton pump inhibitor (PPI) that irreversibly inhibits H+/K+ ATPase in parietal cells, leading to profound suppression of gastric acid secretion. It is one of the most effective drugs for acid suppression and ulcer healing.",
      "correct_choice_id": 273893,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/34995751700132801/34995751700132801.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/34995751700132801/34995751700132801.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 88828,
      "choices": [
        {
          "id": 273897,
          "text": "It is less potent"
        },
        {
          "id": 273898,
          "text": "It is shorter acting"
        },
        {
          "id": 273899,
          "text": "It produces more CNS side effects"
        },
        {
          "id": 273900,
          "text": "It does not have anti-androgenic action"
        }
      ],
      "text": "Ranitidine differs from cimetidine in the following respect,",
      "unique_key": "Q9682376",
      "question_audio": null,
      "question_video": null,
      "map_id": 34358138,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) It does not have anti-androgenic action. Ranitidine differs from cimetidine in that it does not have anti-androgenic effects. Cimetidine has a well-known anti-androgenic action due to its ability to block androgen receptors and inhibit cytochrome P450 enzymes involved in testosterone metabolism. This can lead to gynecomastia, reduced libido, and impotence in some male patients. Ranitidine, however, lacks this anti-androgenic activity, making it a preferable option for long-term use in patients concerned about hormonal side effects. Explanation of Incorrect Options: (A) It is less potent – Incorrect. Ranitidine is actually more potent than cimetidine. It is approximately 5 to 10 times more potent, meaning that a lower dose of ranitidine is required to achieve the same acid-suppressing effect as cimetidine. (B) It is shorter acting – Incorrect. Ranitidine has a longer duration of action compared to cimetidine. While cimetidine requires more frequent dosing (typically four times daily), ranitidine can be given twice daily due to its longer half-life and sustained acid suppression. (C) It produces more CNS side effects – Incorrect. Cimetidine is more likely to cross the blood-brain barrier and cause CNS-related side effects such as confusion, dizziness, and headache, especially in elderly patients. Ranitidine, on the other hand, has a lower tendency to cause CNS side effects because it has a weaker affinity for crossing the blood-brain barrier.",
      "correct_choice_id": 273900,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 88829,
      "choices": [
        {
          "id": 273901,
          "text": "They prevent stress ulcers in the stomach"
        },
        {
          "id": 273902,
          "text": "They cause faster healing of duodenal ulcers"
        },
        {
          "id": 273903,
          "text": "They are the most efficacious drugs in inhibiting gastric acid secretion"
        },
        {
          "id": 273904,
          "text": "They afford the most prompt relief of ulcer pain"
        }
      ],
      "text": "Which of the following can be used to treat heparin induced thromocytopenia condition ? Choose the CORRECT statement about H2 receptor blockers",
      "unique_key": "Q6633108",
      "question_audio": null,
      "question_video": null,
      "map_id": 34884635,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) They prevent stress ulcers in the stomach. H2 receptor blockers such as ranitidine, famotidine, and nizatidine are widely used to prevent stress ulcers, particularly in critically ill patients. Stress ulcers develop due to excessive gastric acid secretion, often triggered by conditions such as severe burns (Curling’s ulcers), trauma, sepsis, or prolonged hospitalization. H2 blockers work by inhibiting histamine-mediated stimulation of gastric acid secretion, thereby reducing the risk of stress-related mucosal damage in the stomach. Incorrect Options: (B) They cause faster healing of duodenal ulcers – Incorrect. While H2 receptor blockers do promote healing of duodenal ulcers, they do not necessarily act faster than proton pump inhibitors (PPIs) like omeprazole. PPIs are more effective in reducing gastric acid secretion, leading to faster ulcer healing compared to H2 blockers. (C) They are the most efficacious drugs in inhibiting gastric acid secretion – Incorrect. Proton pump inhibitors (PPIs) such as omeprazole, pantoprazole, and esomeprazole are significantly more effective at suppressing gastric acid secretion than H2 receptor blockers. H2 blockers only inhibit acid secretion mediated by histamine, while PPIs completely block the final step of acid secretion at the proton pump level, leading to more profound acid suppression. (D) They afford the most prompt relief of ulcer pain – Incorrect. Antacids provide more immediate relief of ulcer pain by directly neutralizing stomach acid. H2 receptor blockers reduce acid secretion gradually, but they do not offer the fastest pain relief. PPIs are also more effective than H2 blockers in long-term pain relief due to stronger acid suppression.",
      "correct_choice_id": 273901,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 88830,
      "choices": [
        {
          "id": 273905,
          "text": "Antacids"
        },
        {
          "id": 273906,
          "text": "Ascorbic acid"
        },
        {
          "id": 273907,
          "text": "Phosphates"
        },
        {
          "id": 273908,
          "text": "Tetracyclines"
        }
      ],
      "text": "A patient Sonia is diagnosed to be having iron deficiency anemia. The agent that can be used to improve the absorption of iron is",
      "unique_key": "Q3683443",
      "question_audio": null,
      "question_video": null,
      "map_id": 34376739,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Ascorbic acid. Ascorbic acid (Vitamin C) enhances iron absorption by reducing ferric iron (Fe3+) to ferrous iron (Fe2+), which is more readily absorbed in the duodenum. Additionally, ascorbic acid prevents iron from forming insoluble and poorly absorbable complexes with dietary inhibitors like phytates and polyphenols. This effect makes ascorbic acid particularly beneficial in patients with iron deficiency anemia, as it helps increase iron bioavailability and uptake by the body. Incorrect Options: (A) Antacids – Incorrect. Antacids, such as calcium carbonate and magnesium hydroxide, can reduce iron absorption by increasing gastric pH. Since iron absorption is more efficient in an acidic environment, neutralizing stomach acid with antacids can hinder iron uptake. (C) Phosphates – Incorrect. Phosphates can bind to iron and form insoluble complexes, making iron less available for absorption. Foods rich in phosphates (such as dairy products) can also interfere with iron absorption and are generally not recommended for patients with iron deficiency anemia. (D) Tetracyclines – Incorrect. Tetracyclines (a class of antibiotics) chelate with iron, forming non-absorbable complexes in the intestine. This significantly reduces the bioavailability of iron and is why iron supplements should not be taken with tetracyclines or other similar antibiotics.",
      "correct_choice_id": 273906,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/25343631700132818/25343631700132818.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/25343631700132818/25343631700132818.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 88831,
      "choices": [
        {
          "id": 273909,
          "text": "Calcium"
        },
        {
          "id": 273910,
          "text": "Carbohydrates"
        },
        {
          "id": 273911,
          "text": "Fatty acids"
        },
        {
          "id": 273912,
          "text": "Vitamin A"
        }
      ],
      "text": "A 35-year-old obese man complains of postprandial, burning chest pain. His physician prescribes pantoprazole. Pantoprazole may impair absorption of which of the following nutrients?",
      "unique_key": "Q6850331",
      "question_audio": null,
      "question_video": null,
      "map_id": 34891207,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Calcium. Pantoprazole is a proton pump inhibitor (PPI) that reduces gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase pump in gastric parietal cells. By lowering stomach acid levels, PPIs can impair calcium absorption because calcium requires an acidic environment for optimal solubility and absorption in the small intestine. Long-term use of PPIs is associated with decreased calcium absorption, leading to an increased risk of osteoporosis and fractures. This effect is more pronounced in elderly patients or individuals with other risk factors for bone loss. Hypochlorhydria (low stomach acid) reduces the conversion of insoluble calcium salts (e.g., calcium carbonate) into an absorbable form. Patients on chronic PPI therapy are advised to ensure adequate calcium intake (preferably calcium citrate, which does not require stomach acid for absorption). Explanation of Incorrect Options: (B) Carbohydrates Incorrect because carbohydrate digestion and absorption are not significantly affected by pantoprazole. Carbohydrate digestion primarily occurs in the small intestine via pancreatic amylase and brush border enzymes. While gastric acid plays a minor role in starch digestion (via salivary amylase in the stomach), the absence of acid does not significantly impair carbohydrate breakdown or absorption. (C) Fatty Acids Incorrect because fat digestion and absorption are not significantly affected by PPIs. Fat digestion occurs mainly in the small intestine and is dependent on bile acids and pancreatic lipase, not gastric acid. Pantoprazole does not interfere with bile production or pancreatic enzyme secretion, so fatty acid absorption remains unaffected. (D) Vitamin A Incorrect because vitamin A absorption is not significantly impaired by pantoprazole. Vitamin A is a fat-soluble vitamin that is absorbed in the small intestine along with dietary fats. Since pantoprazole does not affect bile acid secretion or fat digestion, vitamin A absorption remains largely intact.",
      "correct_choice_id": 273909,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/62742031700306001/62742031700306001.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/62742031700306001/62742031700306001.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 88832,
      "choices": [
        {
          "id": 273913,
          "text": "Misoprostol"
        },
        {
          "id": 273914,
          "text": "Proton pump inhibitors"
        },
        {
          "id": 273915,
          "text": "H2 antagonists"
        },
        {
          "id": 273916,
          "text": "Sucralfate"
        }
      ],
      "text": "Drug of choice for NSAID induced peptic ulcer is:",
      "unique_key": "Q4524250",
      "question_audio": null,
      "question_video": null,
      "map_id": 34573505,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Proton Pump Inhibitors (PPIs). Proton pump inhibitors (PPIs) are the drug of choice for NSAID-induced peptic ulcers because they effectively inhibit gastric acid secretion by irreversibly blocking the H+/K+ ATPase enzyme in the parietal cells. This leads to a marked reduction in gastric acidity, allowing the ulcer to heal and preventing further damage. PPIs such as esomeprazole, omeprazole, and pantoprazole have been shown to be more effective than H2-receptor antagonists and misoprostol in healing NSAID-induced ulcers. They are also better tolerated than misoprostol, which can cause diarrhea and abdominal cramps. Incorrect Options: (A) Misoprostol – Incorrect. Misoprostol is a prostaglandin E1 analog that protects the gastric mucosa by increasing mucus and bicarbonate secretion and reducing acid secretion. While effective for NSAID-induced ulcers, it is less effective than PPIs and causes dose-limiting side effects such as diarrhea and abdominal cramps. Additionally, misoprostol is contraindicated in pregnancy due to its uterotonic effects, which can lead to abortion. (C) H2 Antagonists – Incorrect. H2-receptor antagonists (ranitidine, famotidine) reduce acid secretion by blocking histamine (H2) receptors in the stomach. However, they are less effective than PPIs in healing NSAID-induced ulcers and in preventing recurrence, especially if NSAID use continues. They do not provide sufficient mucosal protection in high-risk patients. (D) Sucralfate – Incorrect. Sucralfate forms a protective barrier over the ulcer site, shielding it from acid and pepsin. However, it does not reduce acid secretion, making it less effective than PPIs in NSAID-induced ulcers. It also requires multiple daily doses and can interfere with the absorption of other drugs.",
      "correct_choice_id": 273914,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 88833,
      "choices": [
        {
          "id": 273917,
          "text": "Proton pump inhibitors (PPIs)"
        },
        {
          "id": 273918,
          "text": "Antacids"
        },
        {
          "id": 273919,
          "text": "Prokinetic agents"
        },
        {
          "id": 273920,
          "text": "Sucralfate"
        }
      ],
      "text": "A 55-year-old man with chronic GERD has been using over-the-counter ranitidine for symptom control. He recently learned about the withdrawal of ranitidine from the market due to safety concerns. Which alternative class of medications can effectively manage his symptoms?",
      "unique_key": "Q3549741",
      "question_audio": null,
      "question_video": null,
      "map_id": 34658533,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Proton Pump Inhibitors (PPIs). PPIs are the most effective class of drugs for managing chronic GERD (gastroesophageal reflux disease). They work by irreversibly inhibiting the H+/K+ ATPase enzyme in gastric parietal cells, leading to profound and long-lasting suppression of gastric acid secretion. This helps in reducing symptoms, promoting healing of esophagitis, and preventing complications such as Barrett’s esophagus and strictures. PPIs like omeprazole, esomeprazole, pantoprazole, and lansoprazole provide superior symptom control compared to H2 receptor blockers, including ranitidine. Incorrect Options: (B) Antacids – Incorrect. Antacids (magnesium hydroxide, aluminum hydroxide, calcium carbonate) work by neutralizing gastric acid and providing quick relief of heartburn symptoms. However, their effect is short-lived, requiring frequent dosing. Antacids do not reduce acid production, making them ineffective for chronic GERD management. (C) Prokinetic Agents – Incorrect. Prokinetic drugs (metoclopramide, domperidone) increase gastric emptying and esophageal sphincter tone, which can help in mild GERD cases. However, they are less effective than PPIs and have significant side effects (e.g., extrapyramidal symptoms with metoclopramide). They are not first-line therapy for chronic GERD. (D) Sucralfate – Incorrect. Sucralfate forms a protective barrier over ulcers and damaged mucosa but does not reduce acid secretion. It is mainly used for peptic ulcer disease, not GERD. It also requires multiple daily doses and can interfere with the absorption of other medications.",
      "correct_choice_id": 273917,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 88834,
      "choices": [
        {
          "id": 273921,
          "text": "Inhibition of gastric acid secretion"
        },
        {
          "id": 273922,
          "text": "Antagonism of dopamine receptors"
        },
        {
          "id": 273923,
          "text": "Stimulation of serotonin receptors"
        },
        {
          "id": 273924,
          "text": "Relaxation of the lower esophageal sphincter"
        }
      ],
      "text": "A 60-year-old female with a history of diabetes presents with gastroparesis. She is prescribed metoclopramide. What is the primary mechanism of action of this medication?",
      "unique_key": "Q9654623",
      "question_audio": null,
      "question_video": null,
      "map_id": 34748706,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Antagonism of dopamine receptors. Metoclopramide is a prokinetic agent that primarily works by antagonizing dopamine (D2) receptors in the gastrointestinal tract and central nervous system. Dopamine normally inhibits gastric motility by reducing acetylcholine release in the enteric nervous system. By blocking D2 receptors, metoclopramide enhances acetylcholine release, which leads to increased gastric motility, accelerated gastric emptying, and improved coordination of peristalsis. This makes it especially useful in gastroparesis, a condition often seen in diabetic patients where gastric emptying is delayed, leading to nausea, bloating, and early satiety. Metoclopramide also has antiemetic effects by blocking D2 receptors in the chemoreceptor trigger zone (CTZ) of the brain, preventing nausea and vomiting. Incorrect Options: (A) Inhibition of gastric acid secretion – Incorrect. Metoclopramide does not significantly reduce gastric acid secretion. Acid suppression is primarily achieved using proton pump inhibitors (PPIs) or H2 receptor antagonists (e.g., omeprazole, ranitidine). While metoclopramide may provide some symptomatic relief from GERD by increasing lower esophageal sphincter tone, it is not a primary acid suppressant. (C) Stimulation of serotonin receptors – Incorrect. Metoclopramide does have partial serotonin (5-HT4) agonist activity, which contributes to its prokinetic effects. However, its primary mechanism remains dopamine receptor antagonism (D2 blockade). Strong serotonin receptor agonists used for prokinetic action include prucalopride, a selective 5-HT4 agonist. (D) Relaxation of the lower esophageal sphincter – Incorrect. Metoclopramide actually increases the tone of the lower esophageal sphincter (LES), preventing acid reflux in GERD patients. Drugs that relax the LES include nitrates, calcium channel blockers, and anticholinergics, which can worsen GERD.",
      "correct_choice_id": 273922,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 88835,
      "choices": [
        {
          "id": 273925,
          "text": "Decreased gastric acidity"
        },
        {
          "id": 273926,
          "text": "Increased gastric motility"
        },
        {
          "id": 273927,
          "text": "Alteration of gut microbiota"
        },
        {
          "id": 273928,
          "text": "Impaired immune response"
        }
      ],
      "text": "A patient receiving long-term PPI therapy develops a case of Clostridium difficile infection. What is the mechanism by which PPIs may increase the risk of this infection?",
      "unique_key": "Q8275244",
      "question_audio": null,
      "question_video": null,
      "map_id": 34357649,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Decreased gastric acidity. Proton pump inhibitors (PPIs) work by inhibiting the H+/K+ ATPase enzyme in the gastric parietal cells, leading to a significant reduction in gastric acid production. Gastric acid plays a crucial role in killing ingested pathogens, including Clostridium difficile spores. Long-term acid suppression allows C. difficile spores to survive and reach the intestines, where they germinate and produce toxins, leading to C. difficile infection (CDI). Studies have shown that prolonged PPI use is associated with an increased risk of CDI, especially in hospitalized and immunocompromised patients. Incorrect Options: (B) Increased gastric motility – Incorrect. PPIs do not increase gastric motility; they primarily affect acid secretion. Drugs that increase gastric motility (prokinetic agents), such as metoclopramide or erythromycin, could theoretically reduce C. difficile colonization by accelerating intestinal transit and limiting bacterial overgrowth. (C) Alteration of gut microbiota – Incorrect. While PPIs may have some indirect effects on gut microbiota, the primary mechanism for increased CDI risk is loss of gastric acid’s protective function rather than direct microbiota alteration. Antibiotics, not PPIs, are the main contributors to gut microbiota disruption, leading to C. difficile overgrowth. (D) Impaired immune response – Incorrect. PPIs do not directly impair immune function. While gastric acid contributes to pathogen defense, PPIs do not suppress immune cell activity in a way that would significantly contribute to CDI.",
      "correct_choice_id": 273925,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 88836,
      "choices": [
        {
          "id": 273929,
          "text": "Reducing gastric pH to increase antibiotic absorption"
        },
        {
          "id": 273930,
          "text": "Inhibiting bacterial protein synthesis"
        },
        {
          "id": 273931,
          "text": "Enhancing mucosal healing"
        },
        {
          "id": 273932,
          "text": "Suppressing gastric motility"
        }
      ],
      "text": "A 45-year-old woman is diagnosed with Helicobacter pylori infection and is started on a triple therapy regimen including a PPI, amoxicillin, and clarithromycin. Which of the following best describes the mechanism by which the PPI enhances the efficacy of this regimen?",
      "unique_key": "Q4026126",
      "question_audio": null,
      "question_video": null,
      "map_id": 34843617,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) This woman is receiving triple therapy for Helicobacter pylori infection: • PPI (proton pump inhibitor) • Amoxicillin • Clarithromycin Role of the PPI in H. pylori treatment: 1. Raises gastric pH: By inhibiting the H?/K? ATPase in parietal cells, PPIs reduce acid secretion, increase gastric pH, and make the environment less acidic. This is actually the opposite of what option A says — PPIs increase, not reduce, pH. 2. Improves antibiotic stability and activity: Certain antibiotics like amoxicillin and clarithromycin work better at higher pH levels. Acid suppression prevents degradation of acid-sensitive antibiotics. 3. Enhances mucosal healing: PPIs reduce acid-mediated damage to the gastric mucosa, allowing ulcers or inflammation caused by H. pylori to heal more effectively. 4. Indirectly reduces bacterial load: By altering the stomach environment, it may make it less hospitable for H. pylori, but the main bacterial killing is from the antibiotics. Why not the other options? A. Reducing gastric pH to increase antibiotic absorption: Incorrect. PPI increases pH (makes it less acidic). B. Inhibiting bacterial protein synthesis: That's the role of clarithromycin, not the PPI. D. Suppressing gastric motility: PPIs don't significantly affect motility.",
      "correct_choice_id": 273931,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 88837,
      "choices": [
        {
          "id": 273933,
          "text": "Ranitidine"
        },
        {
          "id": 273934,
          "text": "Misoprostol"
        },
        {
          "id": 273935,
          "text": "Antacids"
        },
        {
          "id": 273936,
          "text": "Sucralfate"
        }
      ],
      "text": "A 65-year-old woman with a history of peptic ulcer disease presents to her physician with worsening symptoms of abdominal pain and dyspepsia. She has been taking ibuprofen for arthritis. Which medication would be most appropriate to prevent further ulcer complications?",
      "unique_key": "Q1206404",
      "question_audio": null,
      "question_video": null,
      "map_id": 34971920,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Misoprostol. Misoprostol is a prostaglandin E1 (PGE1) analog that helps prevent NSAID-induced peptic ulcers by: Enhancing mucus and bicarbonate secretion, which protects the gastric mucosa. Reducing gastric acid secretion by inhibiting adenylate cyclase in parietal cells. Increasing mucosal blood flow, promoting healing and protection. Since NSAIDs like ibuprofen inhibit prostaglandin synthesis (via COX-1 inhibition), this reduces the protective gastric mucus barrier, increasing the risk of ulcers. Misoprostol counteracts this effect and is specifically recommended for NSAID-induced ulcer prevention. It is particularly useful in high-risk patients (e.g., elderly patients, those with a history of ulcers, or chronic NSAID users). However, misoprostol is contraindicated in pregnancy due to its potential to induce uterine contractions. Explanation of Incorrect Options: (A) Ranitidine – Incorrect. Ranitidine is an H2 receptor antagonist, which reduces gastric acid secretion but is not as effective as misoprostol in preventing NSAID-induced ulcers. Additionally, ranitidine has been withdrawn from the market due to safety concerns related to potential carcinogenic impurities (NDMA contamination). PPIs (e.g., omeprazole) are preferred over H2 blockers for ulcer prevention. (C) Antacids – Incorrect. Antacids (e.g., magnesium hydroxide, aluminum hydroxide) neutralize gastric acid and provide symptomatic relief, but they do not prevent ulcer formation. They require frequent dosing and do not address the underlying NSAID-induced mucosal damage. (D) Sucralfate – Incorrect. Sucralfate forms a protective barrier over the ulcer site and promotes healing, but it does not reduce acid secretion or counteract NSAID-induced prostaglandin inhibition. It is useful for healing existing ulcers but not as effective in preventing NSAID-induced ulcers compared to misoprostol or PPIs.",
      "correct_choice_id": 273934,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 88838,
      "choices": [
        {
          "id": 273937,
          "text": "Proton pump inhibitors (PPIs)"
        },
        {
          "id": 273938,
          "text": "Antacids"
        },
        {
          "id": 273939,
          "text": "Prokinetic agents"
        },
        {
          "id": 273940,
          "text": "Sucralfate"
        }
      ],
      "text": "A 55-year-old man with chronic GERD has been using over-the-counter ranitidine for symptom control. He recently learned about the withdrawal of ranitidine from the market due to safety concerns. Which alternative class of medications can effectively manage his symptoms?",
      "unique_key": "Q3021706",
      "question_audio": null,
      "question_video": null,
      "map_id": 34986247,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Proton pump inhibitors (PPIs). PPIs, such as omeprazole, lansoprazole, and esomeprazole, are the most effective class of medications for managing chronic gastroesophageal reflux disease (GERD). They work by irreversibly inhibiting the H+/K+ ATPase (proton pump) in gastric parietal cells, leading to potent and prolonged suppression of gastric acid secretion. This reduces acid reflux into the esophagus, alleviating symptoms and allowing esophageal healing. PPIs are preferred for patients requiring long-term acid suppression, especially after the withdrawal of ranitidine (an H2 receptor antagonist) due to safety concerns. Explanation of Incorrect Options: (B) Antacids – Incorrect Antacids (e.g., aluminum hydroxide, magnesium hydroxide) neutralize stomach acid but provide only short-term relief. Unlike PPIs, they do not prevent acid production and are not effective for long-term GERD management. (C) Prokinetic agents – Incorrect Drugs like metoclopramide and domperidone enhance gastric motility and promote gastric emptying, but they do not significantly reduce acid secretion. While they may be used in combination therapy for GERD in patients with delayed gastric emptying, they are not the primary treatment. (D) Sucralfate – Incorrect Sucralfate forms a protective barrier over mucosal ulcers, but it does not inhibit acid production. It is mainly used for treating peptic ulcers rather than chronic GERD.",
      "correct_choice_id": 273937,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 88839,
      "choices": [
        {
          "id": 273941,
          "text": "Inhibition of gastric acid secretion"
        },
        {
          "id": 273942,
          "text": "Antagonism of dopamine receptors"
        },
        {
          "id": 273943,
          "text": "Stimulation of serotonin receptors"
        },
        {
          "id": 273944,
          "text": "Relaxation of the lower esophageal sphincter"
        }
      ],
      "text": "A 60-year-old female with a history of diabetes presents with gastroparesis. She is prescribed metoclopramide. What is the primary mechanism of action of this medication?",
      "unique_key": "Q1375979",
      "question_audio": null,
      "question_video": null,
      "map_id": 34327334,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Antagonism of dopamine receptors. Metoclopramide is a prokinetic agent that primarily acts by blocking dopamine D2 receptors in the gastrointestinal (GI) tract and central nervous system. This increases gastric motility and enhances gastric emptying, making it useful in the treatment of gastroparesis, a condition characterized by delayed gastric emptying, commonly seen in diabetic patients. By antagonizing dopamine, metoclopramide removes the inhibitory effect of dopamine on GI motility, leading to enhanced peristalsis, increased gastric contractions, and improved gastric emptying. Additionally, it has an antiemetic effect by acting on the chemoreceptor trigger zone (CTZ) in the brain. Incorrect Options: (A) Inhibition of gastric acid secretion – Incorrect Metoclopramide does not reduce acid production. Proton pump inhibitors (PPIs) and H2 receptor blockers (e.g., ranitidine, famotidine) are used for gastric acid suppression, not prokinetic agents. (C) Stimulation of serotonin receptors – Incorrect While serotonin (5-HT4) receptor agonists can enhance GI motility, metoclopramide’s primary mechanism is dopamine receptor antagonism. Some newer prokinetic drugs like prucalopride act by stimulating 5-HT4 receptors, but this is not the primary action of metoclopramide. (D) Relaxation of the lower esophageal sphincter – Incorrect Metoclopramide actually enhances the tone of the lower esophageal sphincter (LES), preventing acid reflux. Drugs that cause relaxation of the LES, such as nitrates or calcium channel blockers, can worsen GERD symptoms.",
      "correct_choice_id": 273942,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 88840,
      "choices": [
        {
          "id": 273945,
          "text": "Decreased gastric acidity"
        },
        {
          "id": 273946,
          "text": "Increased gastric motility"
        },
        {
          "id": 273947,
          "text": "Alteration of gut microbiota"
        },
        {
          "id": 273948,
          "text": "Impaired immune response"
        }
      ],
      "text": "A patient receiving long-term PPI therapy develops a case of Clostridium difficile infection. What is the mechanism by which PPIs may increase the risk of this infection?",
      "unique_key": "Q2915714",
      "question_audio": null,
      "question_video": null,
      "map_id": 34630903,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Decreased gastric acidity. Proton pump inhibitors (PPIs), such as omeprazole and pantoprazole, are commonly used to reduce gastric acid secretion by inhibiting the H+/K+ ATPase (proton pump) in parietal cells of the stomach. While they are effective in treating gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome, long-term use can increase the risk of infections, including Clostridium difficile (C. difficile) colitis. Gastric acid plays a crucial role in killing ingested bacteria and pathogens before they reach the intestines. By reducing stomach acidity, PPIs allow C. difficile spores to survive and colonize the intestines, leading to diarrhea, colitis, and even severe complications like toxic megacolon. This is why patients on chronic PPI therapy should be carefully monitored for gastrointestinal infections. Explanation of Incorrect Options: (B) Increased gastric motility – Incorrect PPIs do not increase gastric motility; in fact, they have little direct effect on motility. Gastric motility changes (such as delayed gastric emptying) are more commonly seen with prokinetic agents like metoclopramide or domperidone. (C) Alteration of gut microbiota – Incorrect While it is true that changes in gastric acidity can indirectly affect gut microbiota, the primary mechanism by which PPIs increase C. difficile infection is by reducing gastric acidity. The alteration in microbiota is a secondary effect and not the main reason for increased infection risk. (D) Impaired immune response – Incorrect PPIs do not directly impair the immune system. Immunosuppressive drugs (such as corticosteroids or chemotherapy agents) are more commonly associated with immunosuppression and increased infection risk.",
      "correct_choice_id": 273945,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    }
  ]
}